Company / Cash & Equivalents
Annexon, Inc. Cash & Equivalents History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$49.5M
FY2024
5-year range
$49.5M / $268.6M
FY2020-FY2024
Trend
-78.0%
vs FY2023
Sector context
#184 of 209
Health Care
What the data says
Annexon, Inc.'s cash & equivalents of $49M is lower than 88% of companies in the Health Care sector (FY2024). Cash & Equivalents has fluctuated over the past 6 years, ranging from $44M in FY2019 to $269M in FY2020.
Based on SEC 10-K filings.
$49M in FY2024 with a 5-year CAGR of +2.4%.
Declined from $140M to $49M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -12.9%
- 5-Year CAGR
- +2.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 12% in Health CareTop 88% of 209This company $49.5M Sector average $696.0M
▼
-92.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.4%, indicating consistent growth.
- In FY2024, cash & equivalents decreased 78.0% year-over-year.
- Ranks #184 out of 209 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $49.5M | -78.0% |
| FY2023 | $225.1M | +60.8% |
| FY2022 | $140.0M | +87.1% |
| FY2021 | $74.8M | -72.1% |
| FY2020 | $268.6M | +511.3% |
| FY2019 | $43.9M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026